Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Chronic Heart Failure

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 204 articles:
HTML format
Text format



Single Articles


    April 2017
  1. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format    


  2. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    


    March 2017
  3. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format    


  5. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    PubMed     Text format    


  7. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  8. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available


    February 2017

  9. Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  10. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
    Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
    The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    


  12. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
    Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    


  13. BOHM M, Young R, Jhund PS, Solomon SD, et al
    Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Eur Heart J. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    


  14. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2017;38:317-325.
    PubMed     Text format    


  15. LUSCHER TF
    An update on heart failure: from experimental findings to clinical trials.
    Eur Heart J. 2017;38:305-307.
    PubMed     Text format    


  16. TOFIELD A
    Teenage weight and risk for adult heart failure.
    Eur Heart J. 2017;38:311-312.
    PubMed     Text format    


  17. TOFIELD A
    End of the road for aliskiren in heart failure.
    Eur Heart J. 2017;38:312-313.
    PubMed     Text format    



  18. Professor Jay Cohn a pioneer in heart failure.
    Eur Heart J. 2017;38:308-309.
    PubMed     Text format    


    January 2017
  19. BRUNO RM, Taddei S
    Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    Eur Heart J. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format    


  20. LANDIN AM, Hare JM
    The quest for a successful cell-based therapeutic approach for heart failure.
    Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
    PubMed     Text format    


  21. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    


  22. MAGGIONI AP, Ruschitzka F
    The year in cardiology 2016: heart failure.
    Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
    PubMed     Text format    


    December 2016
  23. MAISEL AS, Di Somma S
    Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
    Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
    PubMed     Text format    


  24. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
    Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
    Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
    PubMed     Text format    


  25. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    PubMed     Text format    


  27. MINOIA C, Paolillo S
    Two weeks at Harvard, for two European heart failure trainees.
    Eur Heart J. 2016;37:3553-3554.
    PubMed     Text format    


  28. PAOLILLO S
    The ESC Heart Failure Association postgraduate course in heart failure.
    Eur Heart J. 2016;37:3551-3552.
    PubMed     Text format    


    November 2016
  29. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
    Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
    Eur Heart J. 2016.
    PubMed     Text format    



  30. What the Heart Failure Congress means to the Heart Failure Association.
    Eur Heart J. 2016;37:3124-3126.
    PubMed     Text format    



  31. First European advice launched for acute heart failure.
    Eur Heart J. 2016;37:3123-3124.
    PubMed     Text format    



  32. What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
    Eur Heart J. 2016;37:3121-3122.
    PubMed     Text format    


    October 2016
  33. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
    The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
    Eur Heart J. 2016.
    PubMed     Text format    


  34. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
    How robust are clinical trials in heart failure?
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    September 2016
  35. JORGE C, Hiltrop N, Desmet W
    Heart failure with preserved ejection fraction: blame the veins....
    Eur Heart J. 2016.
    PubMed     Text format    


  36. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
    Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  37. JHUND PS
    Obesity and heart failure: when 'epidemics' collide.
    Eur Heart J. 2016 Sep 22. doi: 10.1093.
    PubMed     Text format    


  38. FRADLEY MG
    The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
    Eur Heart J. 2016;37:2740-2742.
    PubMed     Text format    


  39. ZHABYEYEV P, Oudit GY
    Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    


  40. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    



  41. The Acute Heart Failure Academy.
    Eur Heart J. 2016;37:2568-9.
    PubMed     Text format    


  42. LUSCHER TF
    From heart failure to transplantation: genes, miRNAs, and biomarkers.
    Eur Heart J. 2016;37:2561-3.
    PubMed     Text format    


    August 2016
  43. HADDAD S, Wang Y, Galy B, Korf-Klingebiel M, et al
    Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  44. LAM CS, Teng TK, Tay WT, Anand I, et al
    Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    July 2016
  45. ZANNAD F, Ferreira JP
    Globalization of heart failure trials: no turning back on this paradigm.
    Eur Heart J. 2016.
    PubMed     Text format    


  46. LUSCHER TF
    Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing.
    Eur Heart J. 2016;37:2085-7.
    PubMed     Text format    


  47. HINDRICKS G, Varma N
    Remote monitoring and heart failure: monitoring parameters, technology, and workflow.
    Eur Heart J. 2016.
    PubMed     Text format    


    June 2016
  48. KRISTENSEN SL, Martinez F, Jhund PS, Arango JL, et al
    Geographic variations in the PARADIGM-HF heart failure trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  49. VON ROEDER M, Rommel KP, Blazek S, Daehnert I, et al
    Pressure-volume-loop-guided closure of an iatrogenic atrial septal defect for right heart failure following MitraClip-implantation.
    Eur Heart J. 2016.
    PubMed     Text format    


  50. EPSTEIN M, Pitt BC
    A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden frui
    Eur Heart J. 2016.
    PubMed     Text format    


  51. BORLAUG BA, Kane GC, Melenovsky V, Olson TP, et al
    Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  52. ROSENGREN A, Aberg M, Robertson J, Waern M, et al
    Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  53. LUSCHER TF
    Frontiers in heart failure: assessement, risk factors, and novel genetic and cell-based therapies.
    Eur Heart J. 2016;37:1629-32.
    PubMed     Text format    


  54. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
    Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    May 2016
  55. PONIKOWSKI P, Voors AA, Anker SD, Bueno H, et al
    2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributio
    Eur Heart J. 2016.
    PubMed     Text format    


  56. ANTMAN EM, Bax J, Chazal RA, Creager MA, et al
    Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.
    Eur Heart J. 2016.
    PubMed     Text format    


  57. LUSCHER TF
    Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.
    Eur Heart J. 2016;37:1407-9.
    PubMed     Text format    


    April 2016
  58. NAEGELE M, Hernandez AF, Ruschitzka F
    Finerenone in heart failure: walking a fine line.
    Eur Heart J. 2016.
    PubMed     Text format    


  59. FILIPPATOS G, Anker SD, Bohm M, Gheorghiade M, et al
    A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  60. ARAS MA, Teerlink JR
    Lung ultrasound: a 'B-line' to the prediction of decompensated heart failure.
    Eur Heart J. 2016;37:1252-4.
    PubMed     Text format    


  61. LUSCHER TF
    Imaging as a basis of clinical decision-making in congenital and coronary disease and heart failure.
    Eur Heart J. 2016;37:1171-3.
    PubMed     Text format    


  62. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
    Myocardial strain imaging: how useful is it in clinical decision making?
    Eur Heart J. 2016;37:1196-207.
    PubMed     Text format     Abstract available


  63. PATIL NP, Weymann A, Popov AF, Simon AR, et al
    Chest X-ray in cardiac illness: a tale of four decades.
    Eur Heart J. 2016;37:1243.
    PubMed     Text format    


  64. DESAI AS, Jhund PS
    After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  65. BAHLS M, Felix SB
    Cachexia and right ventricular dysfunction in chronic heart failure: what is the chicken and what the egg?
    Eur Heart J. 2016.
    PubMed     Text format    


  66. SCHWARZL M, Ojeda F, Zeller T, Seiffert M, et al
    Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  67. MADONNA R, Van Laake LW, Davidson SM, Engel FB, et al
    Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  68. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Eur Heart J. 2016;37:1015-23.
    PubMed     Text format    


    March 2016
  69. LUSCHER TF
    Update on hypertension: target blood pressure, comorbidities, and outcome.
    Eur Heart J. 2016;37:921-3.
    PubMed     Text format    


  70. BOHM M, Drexler H, Oswald H, Rybak K, et al
    Fluid status telemedicine alerts for heart failure: a randomized controlled trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  71. AUER J, Wallner M, Windpessl M, Schmidt WM, et al
    Acute decompensated heart failure associated with a heteroplasmic 3243A>G mitochondrial DNA point mutation.
    Eur Heart J. 2016.
    PubMed     Text format    


  72. BRAUNWALD E
    Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
    Eur Heart J. 2016;37:745-6.
    PubMed     Text format    


    February 2016
  73. HULOT JS, Ishikawa K, Hajjar RJ
    Gene therapy for the treatment of heart failure: promise postponed.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  74. SWEDBERG K, Ryden L
    Treatment of diabetes and heart failure: joint forces.
    Eur Heart J. 2016.
    PubMed     Text format    


  75. LOCH A, Geh DJ, Veriah RS
    Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
    Eur Heart J. 2016;37:702.
    PubMed     Text format    


  76. VALENTOVA M, von Haehling S, Bauditz J, Doehner W, et al
    Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  77. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  78. LUSCHER TF
    Heart failure and left ventricular remodelling in HFrEF and HFpEF.
    Eur Heart J. 2016;37:423-4.
    PubMed     Text format    


  79. STROMBERG A, Wodlin P
    CardioPulse; Pocket-sized ultrasound for nurses in heart failure?
    Eur Heart J. 2016;37:434-5.
    PubMed     Text format    


  80. TCHAMBAZ L
    CardioPulse: The second Postgraduate Course in Heart Failure: 2016-2017.
    Eur Heart J. 2016;37:430-1.
    PubMed     Text format    


  81. BORLAUG BA
    Defining HFpEF: where do we draw the line?
    Eur Heart J. 2016;37:463-5.
    PubMed     Text format    


  82. DWECK M, Chin C
    CardioPulse: Settling scores with a failing heart.
    Eur Heart J. 2016;37:433-4.
    PubMed     Text format    


  83. WESTENBRINK BD, van Laake LW, Brugts JJ
    CardioPulse: The Postgraduate Course in Heart Failure.
    Eur Heart J. 2016;37:428-9.
    PubMed     Text format    


  84. DIMARCO A, Mansoubi H, Tanner M
    An unusual cause of left ventricular hypertrophy.
    Eur Heart J. 2016;37:497.
    PubMed     Text format    


  85. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
    Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
    Eur Heart J. 2016;37:473-83.
    PubMed     Text format     Abstract available


  86. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
    Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
    Eur Heart J. 2016;37:484-93.
    PubMed     Text format     Abstract available


    January 2016
  87. FITCHETT D, Zinman B, Wanner C, Lachin JM, et al
    Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  88. PLATZ E, Lewis EF, Uno H, Peck J, et al
    Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patientsdagger.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  89. WANG K, Long B, Liu F, Wang JX, et al
    A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  90. RABER L, Piccolo R
    CardioPulse: Different bleeding scores and which one should we use?
    Eur Heart J. 2016;37:327-31.
    PubMed     Text format    


  91. BUDTS W, Roos-Hesselink J, Radle-Hurst T, Eicken A, et al
    Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2016.
    PubMed     Text format    


  92. NICHOLLS M
    CardioPulse: Cyclosporine to reduce myocardial infarction injury?
    Eur Heart J. 2016;37:210-1.
    PubMed     Text format    


  93. KOMAJDA M, Ruschitzka F
    The year in cardiology 2015: heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    


    December 2015
  94. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
    Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  95. HIGASHI H, Inaba S, Izutani H, Sumimoto T, et al
    An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract.
    Eur Heart J. 2015.
    PubMed     Text format    


    November 2015
  96. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
    One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  97. OLDENBURG O, Wellmann B, Buchholz A, Bitter T, et al
    Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  98. LUSCHER TF
    Infections, infarction, and heart failure: prevention and management.
    Eur Heart J. 2015;36:3033-5.
    PubMed     Text format    


  99. MCMURRAY JJ
    Improving outcomes in heart failure: a personal perspectivedagger.
    Eur Heart J. 2015.
    PubMed     Text format    


  100. SKOURI H, Dickstein K
    Heart failure in the Middle East An Emerging Challenge in a Diverse Environment.
    Eur Heart J. 2015;36:2970-2.
    PubMed     Text format    


  101. VAN VELDHUISEN DJ, Ruilope LM, Maisel AS, Damman K, et al
    Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  102. WANG N, Hung CL, Shin SH, Claggett B, et al
    Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    October 2015
  103. ROSENKRANZ S, Gibbs JS, Wachter R, De Marco T, et al
    Left ventricular heart failure and pulmonary hypertensiondagger.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  104. KATZ AM, Rolett EL
    Heart failure: when form fails to follow function.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    September 2015
  105. KOTECHA D, Piccini JP
    Atrial fibrillation in heart failure: what should we do?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  106. KASTRUP J
    Revival of cytokine therapy in heart failure?
    Eur Heart J. 2015.
    PubMed     Text format    


  107. CIKES M, Solomon SD
    Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  108. FRANCIS GS, Thenappan T
    Beta-blockers in heart failure: do we finally have the last word?
    Eur Heart J. 2015.
    PubMed     Text format    


  109. SOLOMON SD, Claggett B, Lewis EF, Desai A, et al
    Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  110. NICHOLLS M
    Research providing new insights into myocardial infarction injury.
    Eur Heart J. 2015;36:2345-6.
    PubMed     Text format    


  111. LUSCHER TF
    Risk factors for and management of heart failure.
    Eur Heart J. 2015;36:2267-9.
    PubMed     Text format    


    August 2015
  112. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
    Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  113. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
    Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
    Eur Heart J. 2015.
    PubMed     Text format    


  114. GORCSAN J 3RD, Schwartzman D
    Ventricular arrhythmias after cardiac resynchronization therapy: does reverse remodelling reverse risk?
    Eur Heart J. 2015.
    PubMed     Text format    


  115. LUSCHER TF
    Prevention of non-communicable diseases and special causes of heart failure.
    Eur Heart J. 2015;36:2019-2022.
    PubMed     Text format    


  116. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
    Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  117. LUSCHER TF
    Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
    Eur Heart J. 2015;36:1937-9.
    PubMed     Text format    


  118. TAYLOR J
    Depression associated with five-fold increased mortality risk in heart failure patients.
    Eur Heart J. 2015;36:1946.
    PubMed     Text format    


  119. TAYLOR J
    Cognitive impairment predicts worse outcome in heart failure.
    Eur Heart J. 2015;36:1945.
    PubMed     Text format    


  120. TOFIELD A
    Digoxin mortality in heart failure and atrial fibrillation.
    Eur Heart J. 2015;36:1944-5.
    PubMed     Text format    


  121. PERRONE-FILARDI P, Paolillo S, Costanzo P, Savarese G, et al
    The role of metabolic syndrome in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    July 2015
  122. GONZALEZ-LOPEZ E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, et al
    Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  123. CASTANO A, Bokhari S, Maurer MS
    Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format    


  124. CORRADO D, Wichter T, Link MS, Hauer R, et al
    Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
    Eur Heart J. 2015.
    PubMed     Text format    


  125. DICKSTEIN K
    Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues.
    Eur Heart J. 2015.
    PubMed     Text format    


  126. HOENDERMIS ES, Liu LC, Hummel YM, van der Meer P, et al
    Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  127. BORLAUG BA
    Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format    


  128. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
    Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  129. GUO J, Mihic A, Wu J, Zhang Y, et al
    Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  130. MUNZEL T, Gori T, Keaney JF Jr, Maack C, et al
    Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    June 2015
  131. FADINI GP, Avogaro A, Degli Esposti L, Russo P, et al
    Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  132. TOFIELD A
    Blood sugar levels in heart failure patients predict risk of early death, hospitalizations, and diabetes.
    Eur Heart J. 2015;36:1498-9.
    PubMed     Text format    


  133. GIRERD N, Collier T, Pocock S, Krum H, et al
    Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  134. FELKER GM
    Augmenting outcomes in patients with advanced heart failure.
    Eur Heart J. 2015.
    PubMed     Text format    


  135. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
    Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
    Eur Heart J. 2015.
    PubMed     Text format    


  136. PARKER JD
    Therapeutic developments in the therapy of heart failure: lessons to be learned.
    Eur Heart J. 2015.
    PubMed     Text format    


  137. ANKER SD, Coats AJ, Cristian G, Dragomir D, et al
    A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  138. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
    Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
    Eur Heart J. 2015.
    PubMed     Text format    


  139. LUSCHER TF
    Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation.
    Eur Heart J. 2015;36:1415-7.
    PubMed     Text format    


  140. EDNER M, Benson L, Dahlstrom U, Lund LH, et al
    Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  141. CHUNG ES, Miller L, Patel AN, Anderson RD, et al
    Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  142. AMSTEIN R, Luscher TF, Maisano F, Ruschitzka FT, et al
    The new postgraduate course in heart failure (PCHF): update on 1st PCHF and announcement of the 2nd PCHF. A project of the European Society of Cardiology Heart Failure Association, the ESC European Heart Academy, the Zurich Heart House and the Univers
    Eur Heart J. 2015;36:1354-5.
    PubMed     Text format    


    May 2015
  143. DESAI AS, McMurray JJ, Packer M, Swedberg K, et al
    Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  144. MEBAZAA A, Yilmaz MB, Levy P, Ponikowski P, et al
    Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em
    Eur Heart J. 2015.
    PubMed     Text format    


  145. MENASCHE P, Vanneaux V, Hagege A, Bel A, et al
    Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  146. FLORAS JS, Ponikowski P
    The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  147. SLIWA K, Johnson MR, Zilla P, Roos-Hesselink JW, et al
    Management of valvular disease in pregnancy: a global perspective.
    Eur Heart J. 2015;36:1078-89.
    PubMed     Text format     Abstract available


  148. HILFIKER-KLEINER D, Haghikia A, Nonhoff J, Bauersachs J, et al
    Peripartum cardiomyopathy: current management and future perspectives.
    Eur Heart J. 2015;36:1090-7.
    PubMed     Text format     Abstract available


  149. BUCKLEY U, Shivkumar K
    Implantable cardioverter defibrillators: even better than we thought?
    Eur Heart J. 2015.
    PubMed     Text format    


    April 2015
  150. MATHIASEN AB, Qayyum AA, Jorgensen E, Helqvist S, et al
    Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  151. LIM SL, Lam CS, Segers VF, Brutsaert DL, et al
    Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  152. RAPHAEL CE, Finegold JA, Barron AJ, Whinnett ZI, et al
    The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  153. BAVISHI C, Messerli FH, Kadosh B, Ruilope LM, et al
    Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  154. KJEKSHUS J
    Are statins failing in heart failure?
    Eur Heart J. 2015.
    PubMed     Text format    


  155. LUSCHER TF
    An update on heart failure and peripheral arterial disease.
    Eur Heart J. 2015;36:885-7.
    PubMed     Text format    


  156. SOLOMON S, Goncalves A
    CardioPulse: drinking moderate amounts of alcohol is linked to reduced risk of heart failure.
    Eur Heart J. 2015;36:890-1.
    PubMed     Text format    


  157. CONEN D
    Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis.
    Eur Heart J. 2015;36:897-8.
    PubMed     Text format    



  158. Stem cells for heart failure: the experience of writing a Cochrane systematic review.
    Eur Heart J. 2015;36:834-6.
    PubMed     Text format    


  159. DAMMAN K, Testani JM
    The kidney in heart failure: an update.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  160. HILFIKER-KLEINER D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, et al
    A management algorithm for acute heart failure in pregnancy. The Hannover experience.
    Eur Heart J. 2015;36:769-70.
    PubMed     Text format    


    March 2015
  161. PREISS D, Campbell RT, Murray HM, Ford I, et al
    The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  162. FLORAS JS, Bradley TD
    Sleep apnoea in acute heart failure: fluid in flux.
    Eur Heart J. 2015.
    PubMed     Text format    


  163. LUSCHER TF
    Novel prognostic markers and treatment options in heart failure: from palliative to regenerative medicine.
    Eur Heart J. 2015;36:699-701.
    PubMed     Text format    


  164. AMINZADEH MA, Tseliou E, Sun B, Cheng K, et al
    Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy.
    Eur Heart J. 2015;36:751-62.
    PubMed     Text format     Abstract available


  165. SAVVATIS K, Schultheiss HP, Tschope C
    Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a 'deeper' look into patients' prognosis.
    Eur Heart J. 2015;36:708-10.
    PubMed     Text format    


  166. LUSCHER TF
    Heart failure: focus on co-morbidities, inflammation, and heart rate.
    Eur Heart J. 2015;36:635-7.
    PubMed     Text format    


  167. NABETA T, Itatani K, Miyaji K, Ako J, et al
    Vortex flow energy loss reflects therapeutic effect in dilated cardiomyopathy.
    Eur Heart J. 2015;36:637.
    PubMed     Text format    


    February 2015
  168. NAKA KK, Ikonomidis I
    Brachial pulse pressure in heart failure: simple to measure but complex to interpret.
    Eur Heart J. 2015.
    PubMed     Text format    


  169. LUSCHER TF
    Heart failure: the cardiovascular epidemic of the 21st century.
    Eur Heart J. 2015;36:395-7.
    PubMed     Text format    


  170. NICHOLLS M
    Professor Marco Metra discusses his aspirations for the European Journal of Heart Failure as he takes over as editor.
    Eur Heart J. 2015;36:398-9.
    PubMed     Text format    


  171. CALIFF RM
    LCZ696: too good to be true?
    Eur Heart J. 2015;36:410-2.
    PubMed     Text format    


  172. LUBITZ SA, Singh JP
    Biventricular pacing: more is better!
    Eur Heart J. 2015;36:407-9.
    PubMed     Text format    


  173. ANKER SD, Ponikowski P, Mitrovic V, Peacock WF, et al
    Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  174. EWEN S, Bohm M
    Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms.
    Eur Heart J. 2015.
    PubMed     Text format    


    January 2015
  175. SAKATA Y, Shiba N, Takahashi J, Miyata S, et al
    Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  176. KHAYAT R, Jarjoura D, Porter K, Sow A, et al
    Sleep disordered breathing and post-discharge mortality in patients with acute heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  177. JACKSON CE, Castagno D, Maggioni AP, Kober L, et al
    Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  178. BANYPERSAD SM, Fontana M, Maestrini V, Sado DM, et al
    T1 mapping and survival in systemic light-chain amyloidosis.
    Eur Heart J. 2015;36:244-51.
    PubMed     Text format     Abstract available


  179. GONCALVES A, Claggett B, Jhund PS, Rosamond W, et al
    Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  180. VOORS AA, Ruschitzka F
    The year in cardiology: heart failure 2014.
    Eur Heart J. 2015.
    PubMed     Text format    


  181. SUD M, Wang X, Austin PC, Lipscombe LL, et al
    Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    December 2014
  182. LUSCHER TF
    Heart failure: the epidemic of the new century.
    Eur Heart J. 2014;35:3389-90.
    PubMed     Text format    


  183. TAYLOR J
    Scientific highlights from Heart Failure 2014.
    Eur Heart J. 2014;35:3319-20.
    PubMed     Text format    


    November 2014
  184. SHAH AM, Lam CS
    Function over form? Assessing the left atrium in heart failure.
    Eur Heart J. 2014.
    PubMed     Text format    


  185. MCMURRAY J, Packer M, Desai A, Gong J, et al
    A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


  186. KOMAJDA M
    Heart rate in chronic heart failure: an overlooked risk factor.
    Eur Heart J. 2014.
    PubMed     Text format    


  187. GIMELLI A, Lancellotti P, Badano LP, Lombardi M, et al
    Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI).
    Eur Heart J. 2014.
    PubMed     Text format    


  188. SLIWA K
    Tackling heart failure in Africa via innovative research: setting the agenda.
    Eur Heart J. 2014;35:2992-3.
    PubMed     Text format    


  189. VAZIR A, Claggett B, Jhund P, Castagno D, et al
    Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


  190. EWEN S, Mahfoud F
    EuroPCR 2014, Hypertension and Heart Failure Track take-home messages.
    Eur Heart J. 2014;35:2850-1.
    PubMed     Text format    


    September 2014
  191. MIZIA-STEC K, Wybraniec MT, Bochenek T, Gierlaszynska K, et al
    Fulminant variant of Loeffler disease mimicking arrhythmogenic right ventricular cardiomyopathy in the course of enterobiasis.
    Eur Heart J. 2014.
    PubMed     Text format    


  192. CLAEYS MJ
    High-sensitivity troponin: does it predict the shape of the iceberg underneath the surface?
    Eur Heart J. 2014;35:2273-5.
    PubMed     Text format    


  193. KAYE GC, Linker NJ, Marwick TH, Pollock L, et al
    Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    August 2014
  194. FERRARI R, Rizzo P
    The Notch pathway: a novel target for myocardial remodelling therapy?
    Eur Heart J. 2014;35:2140-5.
    PubMed     Text format     Abstract available


  195. NENSA F, Poeppel TD, Krings P, Schlosser T, et al
    Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging.
    Eur Heart J. 2014;35:2173.
    PubMed     Text format    


  196. RUWALD AC, Kutyifa V, Ruwald MH, Solomon S, et al
    The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    July 2014
  197. WELLENS HJ, Schwartz PJ, Lindemans FW, Buxton AE, et al
    Risk stratification for sudden cardiac death: current status and challenges for the future.
    Eur Heart J. 2014;35:1642-51.
    PubMed     Text format     Abstract available


  198. CUYPERS JA, Eindhoven JA, Slager MA, Opic P, et al
    The natural and unnatural history of the Mustard procedure: long-term outcome up to 40 years.
    Eur Heart J. 2014;35:1666-74.
    PubMed     Text format     Abstract available


    June 2014
  199. TAYLOR J
    The effects of obesity and ageing on the heart: are they so different?
    Eur Heart J. 2014;35:1502.
    PubMed     Text format    


  200. MURAOKA H, Higashikuni Y, Ando J, Komuro I, et al
    Cardiac compression by massive mediastinal haematoma due to bleeding from the ectopic bronchial artery.
    Eur Heart J. 2014;35:1567.
    PubMed     Text format    


    May 2014
  201. FANOE S, Kristensen D, Fink-Jensen A, Jensen HK, et al
    Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management.
    Eur Heart J. 2014;35:1306-15.
    PubMed     Text format     Abstract available


  202. CHIN CW, Shah AS, McAllister DA, Joanna Cowell S, et al
    High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    April 2014
  203. SWEDBERG K
    Relaxing from dyspnoea.
    Eur Heart J. 2014;35:1017-8.
    PubMed     Text format    


    December 2013
  204. ONG BH, Chiam PT, Sim DK, Tan TE, et al
    Post-implantation transcatheter aortic valve migration in a left ventricular assist device patient with severe aortic insufficiency.
    Eur Heart J. 2013.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: